LRP1B or TP53 mutations are associated with higher tumor mutational burden and worse survival in hepatocellular carcinoma

Background: Hepatocellular carcinoma (HCC) is one of the most leading causes of cancer-related mortality worldwide. Immune checkpoint inhibitors (ICIs) have been proved to be beneficial for advanced HCC. Tumor mutational burden (TMB) is an important predictor for efficacy of ICIs. However, the genet...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Longrong, Yan, Kai, He, Xigan, Zhu, Hongxu, Song, Jia, Chen, Shiqing, Cai, Shangli, Zhao, Yiming, Wang, Lu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2021
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7738815/
https://www.ncbi.nlm.nih.gov/pubmed/33391418
http://dx.doi.org/10.7150/jca.48983

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7738815/
https://www.ncbi.nlm.nih.gov/pubmed/33391418
http://dx.doi.org/10.7150/jca.48983

Ejemplares similares